P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Q Mao,W Zhang,Y Zhang,B Lin,Q Cao,M Xu
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0166
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Alteration of the microbiota metabolite short chain fatty acids (SCFAs) may contribute to the development of inflammatory bowel disease (IBD). Butyrate, one of the SCFAs produced by bacteria, is known to be beneficial in attenuating intestinal inflammation. However, the mechanisms underlying anti-inflammatory effects of butyrate have not yet been entirely investigated. Methods In vivo, wild-type C57BL/6J mice were given a gavage of sodium butyrate (SB) (0.12g/ml) for 5 days. The mice were then administered 2% dextran sodium sulfate to induce experimental colitis models. Fecal microbiota was analysed by 16S rDNA sequencing. In vitro, HCT116 cell line was used to investigate the protective roles of SB on lipopolysaccharide (LPS)-induced inflammatory response. The levels of inflammatory cytokines, intestinal tight junction and autophagy were detected by western blotting and quantitative polymerase chain reaction. Results We observed that SB treatment significantly attenuated colitis in rodent models with reduced tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and interleukin-1β expression, and tended to restore intestinal barrier dysfunction. Mechanically, we identified that the inclusion of SB enhanced protein level of Atg16l1, which indicated enhanced autophagy function. In vitro cell experiments also proved that mRNA levels of IL-6 and TNF-α were decreased, while autophagy-related Beclin was enhanced. Furthermore, our results revealed a distinct alteration mediated by butyrate in the gut microbiota by restored ratio of Firmicutes/Bacteroides, increasing Erysipelotrichaceae and reduced Desulfovibrio abundance. Conclusion This study provides the first data demonstrating that butyrate supplementation attenuates intestinal inflammation probably via promoting autophagy and regulating intestinal microbiota. Our findings provide new insights into butyrate-mediated remission of IBD and butyrate as a potential modulator for autophagy to prevent and treat IBD.
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: **How does butyrate reduce intestinal inflammation by activating autophagy and regulate the gut microbiota to relieve the symptoms of inflammatory bowel disease (IBD)**. ### Background Short - chain fatty acids (SCFAs) are products of gut microbiota metabolism, and their changes may be related to the development of inflammatory bowel disease (IBD). Butyrate, as one type of SCFAs, has been proven to be beneficial for reducing intestinal inflammation, but its anti - inflammatory mechanism has not been fully elucidated. ### Research Objectives This study aims to explore whether butyrate reduces intestinal inflammation by promoting autophagy and regulating the gut microbiota, thereby providing new insights and potential therapeutic targets for the treatment of IBD. ### Main Findings 1. **In vivo experiments**: - By orally administering sodium butyrate (SB) to mice, the study found that SB treatment significantly alleviated intestinal inflammation in the colitis model induced by 2% dextran sulfate sodium (DSS). - SB treatment reduced the expression of tumor necrosis factor - α (TNF - α), interleukin - 6 (IL - 6) and interleukin - 1β (IL - 1β), and helped to restore the intestinal barrier function. 2. **In vitro experiments**: - In the HCT116 cell line, SB treatment decreased the LPS - induced inflammatory response, as manifested by the decrease in the mRNA levels of IL - 6 and TNF - α, while enhancing the expression of the autophagy - related protein Beclin. 3. **Autophagy mechanism**: - The study found that SB treatment enhanced the expression of the Atg16l1 protein, indicating enhanced autophagy function. 4. **Gut microbiota regulation**: - Butyrate treatment changed the composition of the gut microbiota, specifically manifested as the restoration of the Firmicutes/Bacteroides ratio, an increase in Erysipelotrichaceae, and a decrease in Desulfovibrio. ### Conclusion This study shows that butyrate supplementation reduces intestinal inflammation by promoting autophagy and regulating the gut microbiota, which provides a new mechanistic understanding for the alleviation of IBD and suggests that butyrate may be used as a potential autophagy modulator for the prevention and treatment of IBD. ### Formula Presentation There are few formulas involved in this article, mainly for the statistical analysis of experimental data. For example, in Western Blotting and qPCR results, the following formula may be used to represent the change in gene or protein expression levels: \[ \text{Relative expression level}=\frac{\text{Gray value of target gene/protein}}{\text{Gray value of internal reference gene/protein}} \] These formulas ensure the accuracy and comparability of experimental results.